Intravitreal Injection of Therapeutic Protein for Treatment of Retinal Degeneration
Share This:
                           

About The Author

Siobhan M. Cashman is a research assistant professor at Tufts University in the Sackler graduate school of Biomedical Sciences.  Her work focuses on developing novel models of age-related macular degeneration through over-expression of complement activators such as C3 or complement inhibitors such as Factor H.

                       

Intravitreal Injection of Therapeutic Protein for Treatment of Retinal Degeneration

A number of recent polls in the U.S claim that the fear of going blind is ranked higher than that of any other health issue, including cancer. And yet, over 20 million Americans are living with retinal diseases for which the only prognosis is severe or complete vision loss. Age-related Macular Degeneration (both “wet” and “dry” forms) and Diabetic Retinopathy are the most common causes of vision loss in the U.S., accounting for approximately 18 million sufferers. Another approximately 200,000...

Read more